EZH2 Inhibitors and Retinoic Acid Reprogram Leukemia Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating leukemia, particularly acute myeloid leukemia (AML), have been ineffective due to the inability of induced transcription factors to bind to condensed chromatin, leading to differentiation arrest and continuous expansion of leukemic clones.
Innovation Solution
Administering a combination of histone methyltransferase inhibitors, such as EZH2 inhibitors, and reprogramming agents like all-trans retinoic acid or ISX-9, along with cell cycle inhibitors like palbociclib, to reprogram cancer cells and induce terminal differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If differentiation therapy is applied to induce transcription factors to drive leukemia cell differentiation, then cell proliferation is halted and differentiation is promoted, but the induced transcription factors cannot bind to condensed chromatin of repressed genes, rendering the treatment ineffective
Solution Approach 1:
The patent applies EZH2 inhibition before or concurrently with transcription factor induction to preemptively open chromatin structure. By reducing H3K27me3 marks in advance, the chromatin becomes accessible to transcription factors before they are induced, allowing them to bind to their target sites and drive differentiation effectively.
Solution Approach 2:
The patent introduces EZH2 inhibitors as an intermediary agent that modifies chromatin structure to facilitate the interaction between transcription factors and DNA. The inhibitor acts as a mediator that removes the epigenetic barrier (H3K27me3 marks), enabling the transcription factors to access and bind to their target sequences on condensed chromatin.
2Ease of operation
If transcription factors are induced to bind to DNA and drive differentiation, then leukemia cell maturation is promoted, but the condensed H3K27me3-marked chromatin structure prevents transcription factor access to DNA-binding sites
Solution Approach 1:
The patent changes the epigenetic parameter of chromatin structure by inhibiting EZH2, which reduces H3K27me3 marks. This parameter change transforms the chromatin from a condensed, inaccessible state to a more open, accessible state, allowing transcription factors to bind to DNA while maintaining the overall chromatin organization.
3Productivity
If leukemia cells are maintained in an immature self-renewing stage through differentiation arrest, then continuous expansion of leukemic clones occurs driving disease progression, but inducing differentiation requires overcoming the epigenetic barrier of condensed chromatin
Solution Approach 1:
The patent extracts or removes the epigenetic barrier (H3K27me3 marks) through EZH2 inhibition, separating this restraining factor from the chromatin structure. By taking out the methyl marks that condense chromatin, the patent enables transcription factors to access DNA without having to overcome the full complexity of the condensed chromatin structure.
Data Source
AI summary
The present invention relates to methods and compositions for the treatment of cancer in a subject in need thereof by treatments that reprogram the cancer cells.